Immune Design receives Orphan Drug Designation for G100 intratumoral product candidate
Immune Design announced FDA has granted Orphan Drug Designation for its investigational intratumoral therapy, G100, for treatment of follicular non-Hodgkin’s lymphoma. G100 contains a synthetic small molecule TLR-4 agonist, GLA, and is the lead product candidate in their Antigen Agnostic approach. February 22, 2017